Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.

中文翻译：

---

药物评估：C5a受体拮抗剂PMX-53。

Peptech正在开发PMX-53，一种补体C5a抑制剂，可潜在治疗炎症性疾病，包括类风湿性关节炎和牛皮癣。两种适应症的Ib / IIa期临床试验均已完成。